NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
Clinical Trials
70 trialsNCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
NCT01175356 2026-01-23
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Children's Oncology Group
Phase 1 Completed
NCT01231906 2026-01-23
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Children's Oncology Group
Phase 3 Completed
NCT02101788 2025-11-13
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT05613088 2025-10-20
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT02514447 2025-09-25
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
G1 Therapeutics, Inc.
Phase 1/2 Completed
NCT03107988 2025-09-15
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00186888 2025-09-04
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
St. Jude Children's Research Hospital
Phase 3 Completed
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00308165 2025-06-27
Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
Columbia University
Phase 1 Completed
NCT03554473 2025-05-09
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02487095 2025-04-13
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT05246111 2024-11-22
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT00170625 2024-11-12
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 1/2 Completed
NCT04768296 2024-09-26
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
EMD Serono
Phase 2 Completed
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT00601003 2024-08-06
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Milton S. Hershey Medical Center
Phase 2 Completed
NCT01798004 2024-07-15
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT02200757 2024-06-25
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Completed
NCT01606878 2024-01-05
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT02481830 2023-07-27
CheckMate331
Bristol-Myers Squibb
Phase 3 Completed
NCT00057837 2023-07-05
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00976911 2022-06-21
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02357810 2022-06-07
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
Phase 2 Completed
NCT00567567 2022-04-28
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT01004874 2022-04-13
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Duke University
Phase 2 Completed
NCT00317772 2022-02-07
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed
NCT00499616 2021-07-06
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT03061812 2021-02-23
TAHOE
AbbVie
Phase 3 Completed
NCT03098030 2020-12-09
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
United Therapeutics
Phase 2/3 Completed
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed
NCT02421588 2020-04-03
CORAIL
PharmaMar
Phase 3 Completed
NCT02786719 2020-03-12
SPRING
Baylor College of Medicine
Phase NA Completed
NCT01492673 2019-10-29
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01266447 2019-08-08
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00803062 2019-07-23
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00065182 2019-06-24
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00011986 2019-04-16
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Phase 3 Completed
NCT00087126 2019-01-08
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00064077 2018-10-17
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
GOG Foundation
Phase 3 Completed
NCT00114166 2018-07-24
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00098956 2018-07-23
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00325416 2018-03-14
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00365547 2017-12-28
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00828139 2017-08-21
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed